History of OsteoGeneX Inc. : :
|
July 2006 |
Founding of OsteoGeneX Inc.
|
July 2006 |
OsteoGeneX awarded Phase I SBIR grant from NIH NIAMS.
|
Sep 2006 |
KTEC picks 10 for entrepreneur program. ( Link)
|
Oct 2006 |
OsteoGeneX featured as “Windhover -Selected Start-ups” In Vivo TOC - Windhover Health Care Business Intelligence. ( Link)
|
Feb 2007 |
OsteoGeneX Showcased in Missouri Client Showcase, Jefferson City.
|
Feb 2007 |
OsteoGeneX Awarded Missouri Senate Resolution by Senator Ridgeway. ( Link)
|
April 2007 |
OsteoGeneX Showcased at the MedVestor Conference, Princeton, NJ.
|
May 2007 |
OsteoGeneX presents scientific results at BIO convention, Boston, MA. ( Link)
|
June 2007 |
OsteoGeneX showcased on Missouri Business Net. ( Link)
|
July 2007 |
OsteoGeneX awarded a Kansas Bioscience Authority Research Voucher. ( Link 1, 2)
|
Jul 2007 |
Startup keeps biotech local. ( Link)
|
July 2007 |
OsteoGeneX qualifies for Kansas State Angel Tax Credit.
|
Aug 2007 |
Authority seeks partnerships. ( Link)
|
History of Sclerostin (SOST) : :
|
2001 |
Sclerostin (SOST) positionally cloned by Celltech from an Afrikaner population presenting with 5X increase in bone density and hypothesized to function as a BMP antagonist. ( Link)
|
2002 |
Discovery of Sclerostin as Wnt Antagonist by Drs Ellies and Krumaluf at Stowers Institute. Wise/Sost nucleic acid sequences and amino acid sequences. Patent 20040023356. ( Link)
|
2005 |
Harvard Scientists publish Sclerostin as a ligand for Wnt co-receptor LRP5 and LRP6. ( Link)
|
2006 |
Seminal Publication by Ellies and Krumlauf showing Sclerostin does not bind to the Human High Bone Mass Mutated LRP5 Receptor. Journal Bone Mineral Research. November 2006:21:1738-1749 (doi: 10.1359/jbmr.060810). ( Link)
|
| Faculty of 1000 Medicine |
“This article provides final evidence for the direct interaction between two of the (currently considered) most important targets in bone anabolism, Sclerostin and LRP5. Activating mutations in LRP5 and loss-of-function mutations in SOST encoding Sclerostin are both underlying sclerosing bone dysplasias with strong similarities, both clinically and radiologically.” ~ Wim van Hul (University of Antwerp, Belgium)
|
2006 |
Sclerostin accepted to act on WNT pathway and regulate bone formation. Sclerostin and Wnt Signalling – the Pathway to Bone Strength. J Clinical Endocrinology & Metabolism 2005, 90(12) pg 6471. ( Link)
|
